Business
Inspyr Therapeutics Announces the Initiation of a Phase 2 Clinical Trial of Mipsagargin for Newly Diagnosed Prostate Cancer Patients
Inspyr Therapeutics Announces the Initiation of a Phase 2 Clinical Trial of Mipsagargin for Newly Diagnosed Prostate Cancer Patients.
About this update from Rebus Hldgs Inc.
[{"type":"text","content":"\n \n Inspyr \n Therapeutics, Inc. (OTCQB: NSPX), a biotech company developing a \n novel prodrug therapeutic for the treatment of cancer, today announced \n that the first patient has been treated in a Phase 2 \n investigator-sponsored clinical trial to evaluate the safety and \n activity of mipsagargin in patients newly diagnosed with prostate \n cancer. The trial is being conducted at The University of Texas Health \n Science Center (UTHealth) at Houston with Robert Amato, D.O., Professor \n and Director, University of Texas/Memorial Hermann Cancer Centers, as \n principal investigator. Mipsagargin is a first-in-class agent with a \n novel mechanism of action that targets prostate-specific membrane \n antigen (PSMA), a highly expressed enzyme on the surface of prostate \n cancer cells.\n \n \n The open-label, single-arm Phase 2 clinical trial will enroll patients \n with treatment-naïve prostate cancer prior to surgical removal of the \n tumor. Patients in the trial will be administered mipsagargin by \n intravenous infusion on the first three consecutive days of a 28-day \n cycle, over a total of three cycles. The trial will evaluate the effect \n of mipsagargin on the perfusion and volume of the prostate. Inspyr \n expects top-line results in mid 2017.\n \n \n “Mipsagargin presents a novel tumor-targeting approach to treating \n patients newly diagnosed with prostate cancer,” said Dr. Amato. “My \n colleagues at UTHealth are focused on improving treatment options for \n prostate cancer patients, and we look forward to evaluating \n mipsagargin’s effectiveness in disrupting the blood supply of prostate \n tumors and killing prostate cancer cells, which could lead to tumor \n regression and potentially improved survival rates for patients \n diagnosed with this type of cancer.”\n \n \n “Dr. Amato and his colleagues at UTHealth have identified a potentially \n novel application of mipsagargin for prostate cancer patients, and we \n look to continuing our collaboration,” said Chris Lowe, Inspyr’s \n President and Chief Executive Officer. “We believe mipsagargin’s unique \n mechanism of action delivers a potent therapy to the tumor site while \n maintaining an attractive safety profile. We look forward to reviewing \n the results from this study.”\n \n \n Abo...